Author’s response to reviews

Title: Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- A prospective interventional clinical trial

Authors:

Shafiq Ur Rehman Cheema (shafiqcheema@yahoo.com)
Muhammad Salman Rehman (dr.salmanrehman@hotmail.com)
Ghulam Hussain . (ghkhawaja2@hotmail.com)
Sidra Shafiq Cheema (sidra1@yahoo.com)
Nooman Gilani (ngilani@hotmail.com)

Version: 4 Date: 11 Oct 2019

Author’s response to reviews:

BNEP-D-19-00295R3
Efficacy and tolerability of Sofosbuvir and Daclatasvir for treatment of Hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- A Prospective interventional clinical Trial
Shafiq Ur Rehman Cheema; Muhammad Salman Rehman; Ghulam Hussain .; Sidra Shafiq Cheema; Nooman Gilani
BMC Nephrology

Dear Prof. Dr. Cheema,

Your manuscript "Efficacy and tolerability of Sofosbuvir and Daclatasvir for treatment of Hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- A Prospective interventional clinical Trial" (BNEP-D-19-00295R3) has been assessed by our reviewers. They have raised a number of points which we believe would improve the manuscript and may allow a revised version to be published in BMC Nephrology.

Their reports, together with any other comments, are below. Please also take a moment to check our website at https://www.editorialmanager.com/bnep/ for any additional comments that were saved as attachments. Please note that as BMC Nephrology has a policy of open peer review, you will be able to see the names of the reviewers.

If you are able to fully address these points, we would encourage you to submit a revised manuscript to BMC Nephrology.
Once you have made the necessary corrections, please submit online at:

https://www.editorialmanager.com/bnep/

If you have forgotten your password, please use the 'Send Login Details' link on the login page at https://www.editorialmanager.com/bnep/. For security reasons, your password will be reset.

Please include a cover letter with a point-by-point response to the comments, describing any additional experiments that were carried out and including a detailed rebuttal of any criticisms or requested revisions that you disagreed with. Please also ensure that all changes to the manuscript are indicated in the text by highlighting or using track changes.

Please also ensure that your revised manuscript conforms to the journal style, which can be found at the Submission Guidelines on the journal homepage.

A decision will be made once we have received your revised manuscript, which we expect by 06 Nov 2019.

Please note that you will not be able to add, remove, or change the order of authors once the editor has accepted your manuscript for publication. Any proposed changes to the authorship must be requested during peer-review, and adhere to our criteria for authorship as outlined in BioMed Central's policies. To request a change in authorship, please download the 'Request for change in authorship form' which can be found here - http://www.biomedcentral.com/about/editorialpolicies#authorship. Please note that incomplete forms will be rejected. Your request will be taken into consideration by the editor, and you will be advised whether any changes will be permitted. Please be aware that we may investigate, or ask your institute to investigate, any unauthorized attempts to change authorship or discrepancies in authorship between the submitted and revised versions of your manuscript.

I look forward to receiving your revised manuscript and please do not hesitate to contact us if you have any questions.

Best wishes,

Tillie Cryer
BMC Nephrology
https://bmcnephrol.biomedcentral.com/

Editor Comments:
Your manuscript has been reassessed by the reviewers. Whilst reviewer 1 is satisfied with the revisions made, we agree with Reviewer 2 that an Intention to Treat analysis should be completed, in line with CONSORT guidelines for randomized controlled trials. We kindly ask that this analysis is completed and your methods, results, and discussion are updated accordingly with the relevant data and supporting text.

Response: As per Editor’s and reviewer’s comments, we have performed separate Intention to Treat Analysis and Per-protocol analysis. All relevant changes have been made in manuscript in relation to ITT & PP analysis:
Abstract: Results; Page 02 (Highlighted).
Methods: Statistics; Page 06 (Highlighted).
1. Availability of data and material
The Availability of Data and Materials statement refers to the raw data used in your study and presenting tables and figures. It is not sufficient to state that data 'might' be made available, the full conditions for data access should be stated. Data availability statements can take one of the following forms (or a combination of more than one if required for multiple datasets):

- The datasets generated and/or analysed during the current study are available in the [INSERT NAME] repository, [INSERT PERSISTENT WEB LINK TO DATASETS]
- The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.
- All data generated or analysed during this study are included in this published article [and its supplementary information files].
- The datasets generated and/or analysed during the current study are not publicly available due [INSERT REASON WHY DATA ARE NOT PUBLIC] but are available from the corresponding author on reasonable request.
- Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
- The data that support the findings of this study are available from [third party name] but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of [third party name].
- Not applicable. If your manuscript does not contain any data, please state 'Not applicable' in this section.

Please note that if you do wish to share your raw data and do not have consent from all patients to publish this data it will need to be de-identified.

Please also note that if you include your raw data as a supplementary file you will need to provide, after the References, a section titled “Additional files” where you list the following information about each of your supplementary files: * File name (e.g. Additional file 1), * Title of data, * Description of data. All additional files will also need to have been cited in the main manuscript.

Response: Relevant statement as per suggestion has been included on page 16, Highlighted

2. Acknowledgments
Please expand the acronym 'SEAT' included in your acknowledgements - if this is a funder, please remove this information from the Acknowledgements and include it in the Funding section instead. If you have no further acknowledgements, please put “Not Applicable” in the Acknowledgements section. Please also note that Acknowledgements should only refer to those involved directly in the research. Please remove any personal acknowledgements from this section. if you have no acknowledgments, please state 'Not applicable' under this subsection heading.

Response: Certainly, we have revised the acknowledgment section as suggested. We have removed
SEAT and concerned as per policy. 
Further, we have added acknowledgment of Dr. Syed Muhammad Sharib, as it is relevant to certain manuscript drafting, analysis & publication support only. 
For Funding thing, we do not have any funding receipt from anyone. Simply funding is Not Applicable in our study project. 

BMC Nephrology operates a policy of open peer review, which means that you will be able to see the names of the reviewers who provided the reports via the online peer review system. We encourage you to also view the reports there, via the action links on the left-hand side of the page, to see the names of the reviewers. 

Reviewer reports: 
Masanori Atsukawa (Reviewer 1): Some issue i suggested were appropriately corrected.
Response: Acknowledged. 
Meghan E. Sise (Reviewer 2): I still believe that intention to treat analysis should be performed prior to publication. 
Response: Intention to treat analysis performed, complete response is mentioned above. 

If improvements to the English language within your manuscript have been requested, you should have your manuscript reviewed by someone who is fluent in English. If you would like professional help in revising this manuscript, you can use any reputable English language editing service. We can recommend our affiliates Nature Research Editing Service (http://bit.ly/NRES_BS) and American Journal Experts (http://bit.ly/AJE_BS) for help with English usage. Please note that use of an editing service is neither a requirement nor a guarantee of publication. Free assistance is available from our English language tutorial (https://www.springer.com/gb/authors-editors/authorandreviewertutorials/writinginenglish) and our Writing resources (http://www.biomedcentral.com/getpublished/writing-resources). These cover common mistakes that occur when writing in English.

------------------
Editorial Policies
------------------
Please read the following information and revise your manuscript as necessary. If your manuscript does not adhere to our editorial requirements, this may cause a delay while this is addressed. Failure to adhere to our policies may result in rejection of your manuscript.
In accordance with BioMed Central editorial policies and formatting guidelines, all manuscript submissions to BMC Nephrology must contain a Declarations section which includes the mandatory sub-sections listed below. Please refer to the journal's Submission Guidelines web page for information regarding the criteria for each sub-section (https://bmcnephrol.biomedcentral.com/).

Where a mandatory Declarations section is not relevant to your study design or article type, please write "Not applicable" in these sections.

For the 'Availability of data and materials' section, please provide information about where the data supporting your findings can be found. We encourage authors to deposit their datasets in publicly...
available repositories (where available and appropriate), or to be presented within the manuscript and/or additional supporting files. Please note that identifying/confidential patient data should not be shared. Authors who do not wish to share their data must confirm this under this sub-heading and also provide their reasons. For further guidance on how to format this section, please refer to BioMed Central's editorial policies page (see links below).

Declarations
- Ethics approval and consent to participate
- Consent to publish
- Availability of data and materials
- Competing interests
- Funding
- Authors' Contributions
- Acknowledgements

Further information about our editorial policies can be found at the following links:
Ethical approval and consent:
http://www.biomedcentral.com/about/editorialpolicies#Ethics
Availability of data and materials section:
http://www.biomedcentral.com/submissions/editorial-policies#availability+of+data+and+materials

Recipients of this email are registered users within the Editorial Manager database for this journal. We will keep your information on file to use in the process of submitting, evaluating and publishing a manuscript. For more information on how we use your personal details please see our privacy policy at https://www.springernature.com/production-privacy-policy. If you no longer wish to receive messages from this journal or you have questions regarding database management, please contact the Publication Office at the link below.

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: https://www.editorialmanager.com/bnep/login.asp?a=r). Please contact the publication office if you have any questions.